The updates will be implemented on the Eureka Clinical AI platform.
The Eureka Clinical AI platform, from ConcertAI's TeraRecon, the advanced visualization and clinical AI SaaS category leader, now provides clinicians with the state-of-the-art clinical artificial intelligence and deep learning technology necessary to bring fast and accurate prostate cancer detection and diagnosis using bpMRI and AI in partnership with Bot Image, Inc.
Bot Image, Inc. received FDA clearance for prostate cancer (PCa) screening and detection/diagnosis in July 2022. Bot Image's prostate AI software, ProstatID™, aims to increase the accuracy in PCa detection and diagnosis and has been shown to increase prostate cancer detection while decreasing false positives that may lead to expensive and unwarranted biopsies. Additionally, with its unique FDA clearance for screening using bi-parametric MRI, ProstatID can be used as a regularly planned screening mechanism*. This makes ProstatID an ideal tool for active surveillance to monitor progression of the disease.
Continue reading this story here.
PD-L1 IHC 22C3 pharmD approved to help identify patients who may be eligible to receive treatment with pembrolizumab (Keytruda) to treat gastric or gastroesophageal junction adenocarcinoma.